

Pradeep B Lukka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1453798/publications.pdf>

Version: 2024-02-01

17
papers

146
citations

1307594

7
h-index

1372567

10
g-index

18
all docs

18
docs citations

18
times ranked

151
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. <i>Pharmaceutical Research</i> , 2019, 36, 136.	3.5	19
2	Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. <i>PLoS ONE</i> , 2017, 12, e0172628.	2.5	15
3	X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13072-13095.	6.4	13
4	Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1145-1152.	2.3	10
5	Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1930-1950.		10
6	Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 881-888.	2.0	9
7	Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN) Tj ETQq1.1 0.784314 rgBT (C) 2000-075-260-272	1.1	8
8	Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 151-160.	2.3	8
9	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 25-35.	2.3	8
10	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. <i>Tuberculosis</i> , 2019, 114, 119-122.	1.9	8
11	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. <i>ACS Infectious Diseases</i> , 2021, 7, 2850-2863.	3.8	8
12	A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: Application to in vivo pharmacokinetic and lipophilicity studies in drug development. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 63, 9-16.	2.8	7
13	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0174420.	3.2	7
14	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis. <i>Frontiers in Microbiology</i> , 2018, 9, 1895.	3.5	5
15	Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1103-1114.	4.1	5
16	Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1013-1022.	2.3	4
17	Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. <i>Tuberculosis</i> , 2019, 117, 52-55.	1.9	2